Rare Disease Approved Deal Benchmarks — Ex-US

Understanding Rare Disease Deal Benchmarks at Approved

Approved Rare Disease licensing deals in Ex-US territory command a median upfront payment of $1.9B, with values ranging from $1.3B at the low end to $2.5B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $3.7B to $5.3B, with a median of $4.5B. Royalty rates for rare disease assets at this stage typically fall between 12.7% and 22.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.